SMAD3 and cancer: The inhibitory role of Smad3 on bone marrow-derived NK cell immunity was confirmed in vitro; the cancer-killing activity of NK cells differentiated from Smad3−/− bone marrow cells was significantly higher than the Smad3+/+ control (Supplementary Fig. 8A).